| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9604990 | EAGLE PHARMS | Crystalline forms of pemetrexed diacid and manufacturing processes therefor |
Oct, 2035
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7772209 | EAGLE PHARMS | Antifolate combination therapies |
May, 2022
(1 year, 4 months ago) | |
Pemfexy is owned by Eagle Pharms.
Pemfexy contains Pemetrexed.
Pemfexy has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Pemfexy are:
- US7772209
Pemfexy was authorised for market use on 08 February, 2020.
Pemfexy is available in solution;intravenous dosage forms.
Pemfexy can be used as use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with mesothelioma; use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with non-squamous non-small cell lung cancer.
The generics of Pemfexy are possible to be released after 28 October, 2035.
Drugs and Companies using PEMETREXED ingredient
Market Authorisation Date: 08 February, 2020
Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with mesothelioma; Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administra...
Dosage: SOLUTION;INTRAVENOUS
PEMFEXY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic